Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
OBJECTIVES: To evaluate the clinical efficacy of a novel synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, CLX-090717, in several in vitro cell culture systems and murine CIA, an experimental model of RA. METHODS: Peripheral blood monocytes purified by elutriation, an...
Main Authors: | Sumariwalla, P, Palmer, C, Pickford, L, Feldmann, M, Foxwell, B, Brennan, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
by: Foxwell, B, et al.
Published: (2003) -
P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor.
by: Sumariwalla, P, et al.
Published: (2004) -
Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.
by: Cope, A, et al.
Published: (1993) -
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
by: Foxwell, B, et al.
Published: (2000) -
Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds
by: A Shyam Sunder, et al.
Published: (2013-01-01)